TIDMAGL
RNS Number : 3168A
Angle PLC
28 September 2015
For immediate release 28 September 2015
ANGLE plc ("the Company")
POSTER PUBLICATION AT ESMO ON USE OF PARSORTIX SYSTEM WITH
OVARIAN CANCER PATIENTS
Results further substantiate the value of the Parsortix system
and its applicability in detecting ovarian cancer
ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company,
is pleased to announce that the Medical University of Vienna, one
of its Key Opinion Leaders, has published further highly
encouraging results in support of the use of ANGLE's Parsortix
system in the detection of ovarian cancer.
Further to the announcement on 21 April 2015, the Medical
University of Vienna has extended the work undertaken and published
results from its work with the Parsortix system at the European
Cancer Congress European Society for Medical Oncology ECC 2015,
25-29 September 2015,Vienna ("ESMO"). ESMO is one of the world's
largest and most influential cancer conferences with an estimated
20,000 participants.
The poster can be downloaded from the ANGLE website here
http://www.angleplc.com/the-parsortix-system/download-files/. The
poster describes the results of work using the Parsortix system
with qPCR (quantitative real-time PCR analysis) for downstream
analysis of circulating tumour cells ("Parsortix/qPCR").
The 65 patient study demonstrated the detection of ovarian
cancer at 78/80% sensitivity with 100% specificity, offering the
potential for a much more effective detection of ovarian cancer
than traditional techniques. A larger RNA panel of markers used on
a subset of patients yielded even higher sensitivity whilst
retaining 100% specificity.
The new data reported at ESMO relates to a comparison of
Parsortix/qPCR with conventional immune-fluorescent staining
("IF"). The main finding was that Parsortix/qPCR clearly
out-performed conventional IF staining. This was particularly
pronounced in ovarian cancer where IF was effective in only 25% of
patients compared to 78/80% when using Parsortix/qPCR.
This work further substantiates the value of the Parsortix
system and its applicability in detecting ovarian cancer. ANGLE is
working with Medical University of Vienna and other leading cancer
centres to demonstrate through clinical studies the capability to
triage patients having surgery for abnormal pelvic mass into those
with high and low risk of ovarian cancer so that they can receive
appropriately targeted treatment.
ANGLE estimates that the ovarian cancer sales potential for the
Parsortix system in Europe and the United States would be in excess
of GBP300 million per annum.
Dr Eva Obermayr, Principal Investigator at the Medical
University of Vienna, commented:
"The Parsortix technology clearly outperforms conventional
immune-fluorescent staining. The use of qPCR with the Parsortix
system is both highly sensitive and specific and offers the
potential for a liquid biopsy (simple blood test) to diagnose
ovarian cancer. This would greatly improve the standard of the care
that can be offered to women with this condition."
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"Detection of ovarian cancer is ANGLE's first clinical
application for our Parsortix system. The continued strong results
from Medical University of Vienna are impressive."
For further information:
ANGLE plc 01483 685830
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
Cenkos Securities
Stephen Keys, Dr Christopher Golden
(Nominated adviser)
Russell Kerr, Olly Baxendale (Sales) 020 7397 8900
FTI Consulting
Simon Conway, Mo Noonan, Stephanie
Cuthbert 020 3727 1000
Kimberley Ha (US) 001 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a specialist medtech company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in the United States, China and Australia and three
extensive families of patents are being progressed worldwide. The
system is based on a microfluidic device that captures cells based
on a combination of their size and compressibility. The Parsortix
system is established with strong positive evaluations from leading
cancer research centres and is working with these cancer centres to
demonstrate key applications. Parsortix has a CE Mark for Europe
and FDA authorisation is in process for the United States.
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi $billion clinical market. The Parsortix system
is designed to be compatible with existing major medtech analytical
platforms and to act as a companion diagnostic for major pharma in
helping to identify patients that will benefit from a particular
drug and then monitoring the drug's effectiveness.
Now that the Parsortix system has been developed, ANGLE is
focused on its commercialisation in the market.
ANGLE is strongly focused on establishing the use of the
Parsortix system in clinical practice. To achieve this, ANGLE has
established formal collaborations with world-class cancer centres.
These Key Opinion Leaders are working to identify applications with
medical utility (clear benefit to patients), and to secure clinical
data that demonstrates that utility in patient studies. ANGLE
believes this is the optimal approach for unlocking the
multi-billion dollar worldwide market available to the Company and
its potential strategic partners. Details are available here
http://www.angleplc.com/the-company/collaborators/
As well as cancer, the Parsortix technology has the potential
for deployment with several other important cell types in the
future.
ANGLE began trading on the AIM market of the London Stock
Exchange in March 2004 under the ticker symbol AGL. For further
information please visit: www.angleplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUBUWRVRAKUAR
(END) Dow Jones Newswires
September 28, 2015 02:01 ET (06:01 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024
